157 related articles for article (PubMed ID: 12888933)
1. Tissue factor-dependent coagulation activation and impaired fibrinolysis in situ in gastric cancer.
Wojtukiewicz MZ; Sierko E; Zacharski LR; Zimnoch L; Kudryk B; Kisiel W
Semin Thromb Hemost; 2003 Jun; 29(3):291-300. PubMed ID: 12888933
[TBL] [Abstract][Full Text] [Related]
2. Localization of blood coagulation factors in situ in pancreatic carcinoma.
Wojtukiewicz MZ; Rucinska M; Zacharski LR; Kozlowski L; Zimnoch L; Piotrowski Z; Kudryk BJ; Kisiel W
Thromb Haemost; 2001 Dec; 86(6):1416-20. PubMed ID: 11776308
[TBL] [Abstract][Full Text] [Related]
3. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
[TBL] [Abstract][Full Text] [Related]
4. Occurrence of components of fibrinolytic pathways in situ in laryngeal cancer.
Wojtukiewicz MZ; Sierko E; Zacharski LR; Rózanska-Kudelska M; Zimnoch L
Semin Thromb Hemost; 2003 Jun; 29(3):317-20. PubMed ID: 12888936
[TBL] [Abstract][Full Text] [Related]
5. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
Erem C; Nuhoglu I; Kocak M; Yilmaz M; Sipahi ST; Ucuncu O; Ersoz HO
Endocrine; 2008 Jun; 33(3):270-6. PubMed ID: 19016004
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical localization of coagulation, fibrinolytic and antifibrinolytic markers in adenocarcinoma of the lung.
Nakstad B; Lyberg T
APMIS; 1991 Nov; 99(11):981-8. PubMed ID: 1720319
[TBL] [Abstract][Full Text] [Related]
7. [Expression evaluation of in loco coagulation system in colorectal cancer].
Sierko E; Tokajuk P; Butkiewicz A; Sulkowski S; Zimnoch L; Wojtukiewicz MZ
Pol Merkur Lekarski; 2005 Feb; 18(104):176-9. PubMed ID: 17877125
[TBL] [Abstract][Full Text] [Related]
8. Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Moritz TE; Rousseau SM; Stump DC
Cancer; 1991 Mar; 67(5):1377-83. PubMed ID: 1703919
[TBL] [Abstract][Full Text] [Related]
9. Blood coagulation and fibrinolysis in patients with hyperthyroidism.
Erem C; Ersoz HO; Karti SS; Ukinç K; Hacihasanoglu A; Değer O; Telatar M
J Endocrinol Invest; 2002 Apr; 25(4):345-50. PubMed ID: 12030606
[TBL] [Abstract][Full Text] [Related]
10. Endothelial cell activation in cutaneous vasculitis.
Jurd KM; Stephens CJ; Black MM; Hunt BJ
Clin Exp Dermatol; 1996 Jan; 21(1):28-32. PubMed ID: 8689765
[TBL] [Abstract][Full Text] [Related]
11. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity.
Erem C
Clin Endocrinol (Oxf); 2006 Mar; 64(3):323-9. PubMed ID: 16487444
[TBL] [Abstract][Full Text] [Related]
12. Blood coagulation, fibrinolytic, and inhibitory proteins in end-stage renal disease: effect of hemodialysis.
Vaziri ND; Gonzales EC; Wang J; Said S
Am J Kidney Dis; 1994 Jun; 23(6):828-35. PubMed ID: 8203365
[TBL] [Abstract][Full Text] [Related]
13. Malignant melanoma. Interaction with coagulation and fibrinolysis pathways in situ.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Am J Clin Pathol; 1990 Apr; 93(4):516-21. PubMed ID: 1690950
[TBL] [Abstract][Full Text] [Related]
14. Abnormal regulation of coagulation/fibrinolysis in small cell carcinoma of the lung.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Cancer; 1990 Feb; 65(3):481-5. PubMed ID: 2153429
[TBL] [Abstract][Full Text] [Related]
15. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
Prasad RN; Koh SC; Viegas OA; Ratnam SS
Clin Appl Thromb Hemost; 1999 Jan; 5(1):60-70. PubMed ID: 10725985
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
17. Time course of hemostatic abnormalities in sepsis and its relation to outcome.
Lorente JA; García-Frade LJ; Landín L; de Pablo R; Torrado C; Renes E; García-Avello A
Chest; 1993 May; 103(5):1536-42. PubMed ID: 8486040
[TBL] [Abstract][Full Text] [Related]
18. Indirect activation of blood coagulation in colon cancer.
Wojtukiewicz MZ; Zacharski LR; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Stump DC
Thromb Haemost; 1989 Dec; 62(4):1062-6. PubMed ID: 2694422
[TBL] [Abstract][Full Text] [Related]
19. Pathways of coagulation activation in situ in rheumatoid synovial tissue.
Zacharski LR; Brown FE; Memoli VA; Kisiel W; Kudryk BJ; Rousseau SM; Hunt JA; Dunwiddie C; Nutt EM
Clin Immunol Immunopathol; 1992 May; 63(2):155-62. PubMed ID: 1611717
[TBL] [Abstract][Full Text] [Related]
20. The effect of 17 beta-oestradiol on variables of coagulation and fibrinolysis in postmenopausal women with type 2 diabetes mellitus.
Brussaard HE; Leuven JA; Krans HM; Kluft C
Vascul Pharmacol; 2002 Aug; 39(3):141-7. PubMed ID: 12616982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
